Silexion Therapeutics Corp Ordinary Shares (SLXN) Stock Price

SLXNStock
$0.3699.49%52W
Market Cap$2.03M
P/E
PEG Ratio
Div yield
Beta-0.27

SLXN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-108.92%
Price vs S&P 500 (4W)-88.05%
VGM Score2.83

SLXN Earnings Surprise History

Q3 25-28.80est. -34.00
Q1 26-8.50est. -12.90
Q2 26-5.17est. -2.12

SLXN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.13
4.00

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
SLXNSilexion Therapeutics Corp Ordinary Shares
F$0.36
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Silexion Therapeutics Corp Ordinary Shares

Silexion Therapeutics is a clinical-stage biotechnology company developing targeted treatments for KRAS-driven cancers. Its lead product candidate, SIL204, is a locally administered siRNA designed to treat locally advanced pancreatic cancer in combination with standard chemotherapy, specifically targeting tumors with KRAS G12D and G12V mutations. The company focuses on non-resectable cases where surgical removal is not possible.